Atlantic Trust Group LLC raised its stake in shares of Celgene Corporation (NASDAQ:CELG) by 7.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 285,484 shares of the biopharmaceutical company’s stock after buying an additional 20,820 shares during the period. Atlantic Trust Group LLC’s holdings in Celgene Corporation were worth $35,523,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Bank of New York Mellon Corp increased its position in shares of Celgene Corporation by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock worth $1,255,309,000 after buying an additional 472,067 shares during the period. American Century Companies Inc. increased its position in shares of Celgene Corporation by 4.4% in the first quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock worth $816,733,000 after buying an additional 276,089 shares during the period. Pioneer Investment Management Inc. increased its position in shares of Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after buying an additional 710,584 shares during the period. Prudential Financial Inc. increased its position in shares of Celgene Corporation by 0.9% in the first quarter. Prudential Financial Inc. now owns 2,763,704 shares of the biopharmaceutical company’s stock worth $343,887,000 after buying an additional 24,250 shares during the period. Finally, Swiss National Bank increased its position in shares of Celgene Corporation by 27.2% in the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock worth $341,796,000 after buying an additional 588,000 shares during the period. 79.43% of the stock is currently owned by institutional investors.

Celgene Corporation (CELG) traded up 2.50% during trading on Thursday, hitting $137.70. 2,178,362 shares of the company were exchanged. The company has a market capitalization of $107.73 billion, a price-to-earnings ratio of 42.64 and a beta of 1.89. The company has a 50-day moving average of $133.39 and a 200-day moving average of $125.39. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $139.00.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue was up 18.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.44 earnings per share. Analysts forecast that Celgene Corporation will post $7.32 EPS for the current year.

WARNING: “Atlantic Trust Group LLC Acquires 20,820 Shares of Celgene Corporation (CELG)” was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/atlantic-trust-group-llc-acquires-20820-shares-of-celgene-corporation-celg/1534168.html.

CELG has been the subject of a number of analyst reports. BTIG Research downgraded shares of Celgene Corporation from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $96.93 to $131.70 in a research report on Friday, June 30th. Leerink Swann reiterated an “outperform” rating and issued a $160.00 price objective (up previously from $150.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Argus upgraded shares of Celgene Corporation from a “hold” rating to a “buy” rating and upped their price objective for the stock from $96.93 to $160.00 in a research report on Monday, July 31st. Credit Suisse Group set a $148.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 6th. Finally, Cann reiterated a “buy” rating on shares of Celgene Corporation in a research report on Wednesday, June 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating and twenty-three have assigned a buy rating to the stock. Celgene Corporation currently has a consensus rating of “Buy” and an average price target of $147.38.

In related news, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the transaction, the insider now owns 4,004 shares of the company’s stock, valued at $481,200.72. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Robert J. Hugin sold 175,970 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the transaction, the insider now directly owns 1,033,909 shares in the company, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. Insiders sold 253,761 shares of company stock valued at $33,792,445 over the last three months. 0.95% of the stock is owned by insiders.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.